Antibodies in Action: Role of Human Opsonins in Killing Salmonella enterica Serovar Typhi

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD− S. Typhi-specific IgA and IgG B memory cells in humans

(2010) Rezwanul Wahid et al.   CLINICAL IMMUNOLOGY

The Vi Capsular Polysaccharide Prevents Complement Receptor 3-Mediated Clearance ofSalmonella entericaSerotype Typhi

(2010) R. Paul Wilson et al.   INFECTION AND IMMUNITY

A Randomised Trial Evaluating the Safety and Immunogenicity of the Novel Single Oral Dose Typhoid Vaccine M01ZH09 in Healthy Vietnamese Children

(2010) Tran Tinh Hien et al.   PLoS One

In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7×1010 colony-forming units

(2010) C.E. Lyon et al.   VACCINE

Kinetics of the Natural, Humoral Immune Response to Salmonella enterica Serovar Typhi in Kathmandu, Nepal

(2009) A. S. Pulickal et al.   Clinical and Vaccine Immunology

Salmonella enterica serovar Typhi live vector vaccines finally come of age

(2009) James E Galen et al.   IMMUNOLOGY AND CELL BIOLOGY

Addressing the Global Disease Burden of Typhoid Fever

(2009) Zulfiqar A. Bhutta   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India

(2009) Dipika Sur et al.   NEW ENGLAND JOURNAL OF MEDICINE

Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods

(2009) Anna Lundgren et al.   VACCINE

Early cellular responses toSalmonellainfection: dendritic cells, monocytes, and more

(2008) Miguel A. Tam et al.   IMMUNOLOGICAL REVIEWS